Payment overview · 2025
General Payments
$550.56
35 reported records · 6 companies
Healthcare provider profile · identity verified
Douglas W Midcap, DO
Allopathic & Osteopathic Physicians|Family Medicine · WHEELING, WV · NPI 1992701197
Verified facts
What the public records show
CMS Open Payments records show Douglas W Midcap, DO received $550.56 in general payments during 2025 across 35 reported records.
Abbott Laboratories accounted for 51.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $283.95 | 51.6% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $139.77 | 25.4% | 14 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $50.45 | 9.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $43.87 | 8.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.84 | 3.1% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $15.68 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $550.56 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $283.95 | 14 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $105.48 | 11 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $36.27 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $27.32 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $27.32 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.23 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.94 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 135 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 119 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
57 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
119 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
135 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 503 | 169 |
| Atorvastatin Calcium | Atorvastatin Calcium | 388 | 120 |
| Amlodipine Besylate | Amlodipine Besylate | 385 | 117 |
| Meloxicam | Meloxicam | 357 | 96 |
| Omeprazole | Omeprazole | 351 | 125 |
| Hydrochlorothiazide | Hydrochlorothiazide | 311 | 97 |
| Gabapentin | Gabapentin | 306 | 55 |
| Simvastatin | Simvastatin | 279 | 91 |
| Levothyroxine Sodium | Levothyroxine Sodium | 270 | 83 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 247 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 221 | 73 |
| Furosemide | Furosemide | 220 | 76 |
| Metformin Hcl | Metformin Hcl | 208 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 207 | 61 |
| Alprazolam | Alprazolam | 206 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 199 | 58 |
| Lorazepam | Lorazepam | 191 | 31 |
| Losartan Potassium | Losartan Potassium | 190 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 181 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 161 | 49 |
| Sertraline Hcl | Sertraline Hcl | 148 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 143 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 143 | 28 |
| Famotidine | Famotidine | 142 | 45 |
| Potassium Chloride | Potassium Chloride | 139 | 40 |
| Eliquis | Apixaban | 135 | 27 |
| Tramadol Hcl | Tramadol Hcl | 134 | 35 |
| Trazodone Hcl | Trazodone Hcl | 128 | 30 |
| Ibuprofen | Ibuprofen | 125 | 43 |
| Ozempic | Semaglutide | 119 | 20 |
| Allopurinol | Allopurinol | 118 | 34 |
| Glipizide | Glipizide | 117 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 108 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 104 | 30 |
| Prednisone | Prednisone | 103 | 46 |
| Celecoxib | Celecoxib | 99 | 23 |
| Atenolol | Atenolol | 97 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 95 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 29 |
| Cefdinir | Cefdinir | 86 | 52 |
| Montelukast Sodium | Montelukast Sodium | 83 | 29 |
| Buspirone Hcl | Buspirone Hcl | 78 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 75 | suppressed |
| Azithromycin | Azithromycin | 69 | 47 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 69 | 47 |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 63 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 15 |
| Diazepam | Diazepam | 59 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 18 |
| Pregabalin | Pregabalin | 57 | 12 |
| Synthroid | Levothyroxine Sodium | 57 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 19 |
| Januvia | Sitagliptin Phosphate | 55 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 55 | 16 |
| Metformin Hcl Er | Metformin Hcl | 54 | 18 |
| Meclizine Hcl | Meclizine Hcl | 49 | 15 |
| Methocarbamol | Methocarbamol | 49 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | 11 |
| Ezetimibe | Ezetimibe | 47 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 47 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 13 |
| Spironolactone | Spironolactone | 45 | suppressed |
| Carvedilol | Carvedilol | 44 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | suppressed |
| Baclofen | Baclofen | 41 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 41 | suppressed |
| Finasteride | Finasteride | 40 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 38 | 12 |
| Venlafaxine Hcl | Venlafaxine Hcl | 38 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 38 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 37 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Hydrocortisone | Hydrocortisone | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | 11 |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 32 | 16 |
| Glimepiride | Glimepiride | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | 13 |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | 11 |
| Valsartan | Valsartan | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 18 |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 19 |
| Phenobarbital | Phenobarbital | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 11 |
| Estradiol (Once Weekly) | Estradiol | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | suppressed |
| Niacin Er | Niacin | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Corlanor | Ivabradine Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Klor-Con M10 | Potassium Chloride | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $550.56 · 35 records | Abbott Laboratories | COLLAGENASE SANTYL, Cologuard Collection Kit, ELIQUIS, FREESTYLE LIBRE 3, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error